Participated · Equity · Aug 2026

Provirex traces its scientific origins to research beginning in 2007 and was founded as a spin-off in 2019 to commercialize the Brec1 recombinase technology that cuts out integrated HIV DNA from infected T-helper cells. Preclinical studies demonstrated efficacy in human cells implanted into mice with favorable immunological and toxicological profiles. The company has built in-house laboratory and production capacity—relocating to a full floor at tecHHub in Altona—and expanded its team to just under 20 employees under CEO Dr. Jan Claas-von Jachmann, who joined in March 2025. Provirex is preparing a first-in-human, ex vivo clinical trial in multiple German university hospitals involving eight patients whose stem cells will be engineered with Brec1 and re-infused following busulfan conditioning. Management plans to conduct production in-house and pursue a longer-term goal of in vivo delivery, targeting a potential large-scale market launch around 2033. Financially, the company has raised seed and follow-on investments from IFB-linked funds, Ascencion, Bioventure and InnoVentureFonds, and reports funding secured through the end of 2027 to advance the clinical program.

Participated · Series A · Jan 2022

Juncell Therapeutics is focused on developing personalized TIL therapies for the treatment of solid tumors. The company says it has systematically optimized its cell culture processes and established an independent quality management system aligned with GMP specifications. Juncell reports achieving internationally advanced levels on metrics such as culture success rate, cell count, and cytotoxic activity. Clinically, its TIL therapy has shown strong efficacy in several patients with advanced solid tumors even without intensive lymphodepletion and IL-2 injection. The company also reports improved safety because patients have been treated in general wards. Juncell intends to focus on the TIL field and accelerate clinical development across multiple TIL pipelines, supported by recent financing.

Led · Series A · Sep 2019

DiaMonTech AG is a Berlin-based MedTech company focused on revolutionizing diabetes care through a patented, non-invasive blood-glucose monitoring technology. The device enables users to measure glucose levels without finger-pricking, aiming to improve patient comfort and compliance. The company has received multiple accolades, including the Health-i Award and the Berlin Senate’s Deep Tech Award, underscoring its technological credibility. Newly secured funding will be directed toward obtaining regulatory approvals and launching the product in European and U.S. markets. Management views the latest investment as validation of strong support for deep-tech innovation from German and international backers. While no specific revenue or user figures were disclosed, the fresh capital positions DiaMonTech to transition from development to commercial rollout and scale its operations internationally.

Participated · Series A · Nov 2018

Kanova is a China-based biotherapeutics developer focused on antibodies targeting cancer and autoimmune diseases. Founded in 2015, the company says it has developed three first-in-class drugs and one best-in-class drug, plus earlier-stage candidates targeting tumour immunity and autoimmune disease. Its first medicine for autoimmune diseases was licensed to Livzon Mabpharm for manufacturing in 2017. Kanova has three patent collaboration agreements in place. The company intends to advance earlier-stage candidates toward investigational new drug (IND) status and planned clinical studies. It also plans to use new funding to recruit additional medical personnel to support development.